Indefinite Delivery Contract SPE2DU25D9161

The Defense Logistics Agency (DLA) Troop Support Medical Supply Chain is planning to issue a solicitation for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) to establish multiple prime vendor contracts for providing worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, U.S. Coast Guard, and U.S. Naval Fleet. The contracts will have a 30-month base period and three 30-month option periods, with an estimated total value of $30.3 billion. Awards will be made on a regional basis, with at least three different contractors to be selected across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. Both primary and backup suppliers will provide separate distribution fees for brand/generic and specialty pharmaceuticals to support normal and contingency operations globally. The solicitation is expected to be issued in March 2024 and remain open for 45 days, with no set-aside designation.

The incumbent prime contractor, DMS Pharmaceutical Group Inc., is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, that specializes in providing a comprehensive range of pharmaceutical products and medical supplies to federal government agencies, particularly the DoD. DMS Pharmaceutical Group currently holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a wide portfolio of pharmaceutical items to support the medical supply needs of military health facilities worldwide.